Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.
复制标题
DOI：
10.1126/scitranslmed.3005616
复制
发表时间：
2013-04-03
影响因子：
17.1
通讯作者：
Toner M
中科院分区：
文献类型：
--
作者：
Ozkumur E;Shah AM;Ciciliano JC;Emmink BL;Miyamoto DT;Brachtel E;Yu M;Chen PI;Morgan B;Trautwein J;Kimura A;Sengupta S;Stott SL;Karabacak NM;Barber TA;Walsh JR;Smith K;Spuhler PS;Sullivan JP;Lee RJ;Ting DT;Luo X;Shaw AT;Bardia A;Sequist LV;Louis DN;Maheswaran S;Kapur R;Haber DA;Toner M
循环肿瘤细胞（CTC）从原发性和转移性肿瘤沉积物脱落到血流中。它们的分离和分析对于侵袭性癌症的早期检测和晚期疾病的管理具有很大的希望，但技术障碍限制了它们的广泛临床用途。我们描述了一种惯性聚焦增强的微流体CTC捕获平台，称为“CTC-iChip”，其能够以107个细胞/s从全血中分选稀有CTC。最重要的是，iChip能够使用依赖于或不依赖于肿瘤膜表位的策略分离CTC，因此适用于几乎所有癌症。我们特别证明了iChip在上皮和非上皮癌（包括肺癌、前列腺癌、胰腺癌、乳腺癌和黑色素瘤）中的广泛应用。将CTC分选为溶液中的未固定细胞允许应用高质量的临床标准化形态学和免疫组织化学分析，以及基于RNA的单细胞分子表征。无偏倚、广泛适用、高通量和可自动化的稀有细胞分选技术与普遍接受的分子测定和细胞学标准的组合将使基于CTC的诊断整合到癌症的临床管理中。
Circulating tumor cells (CTCs) are shed into the bloodstream from primary and metastatic tumor deposits. Their isolation and analysis hold great promise for the early detection of invasive cancer and the management of advanced disease, but technological hurdles have limited their broad clinical utility. We describe an inertial focusing–enhanced microfluidic CTC capture platform, termed “CTC-iChip,” that is capable of sorting rare CTCs from whole blood at 107 cells/s. Most importantly, the iChip is capable of isolating CTCs using strategies that are either dependent or independent of tumor membrane epitopes, and thus applicable to virtually all cancers. We specifically demonstrate the use of the iChip in an expanded set of both epithelial and nonepithelial cancers including lung, prostate, pancreas, breast, and melanoma. The sorting of CTCs as unfixed cells in solution allows for the application of high-quality clinically standardized morphological and immunohistochemical analyses, as well as RNA-based single-cell molecular characterization. The combination of an unbiased, broadly applicable, high-throughput, and automatable rare cell sorting technology with generally accepted molecular assays and cytology standards will enable the integration of CTC-based diagnostics into the clinical management of cancer.
登录
查看更多内容
影响因子：
28.2
作者：
Miyamoto DT;Lee RJ;Stott SL;Ting DT;Wittner BS;Ulman M;Smas ME;Lord JB;Brannigan BW;Trautwein J;Bander NH;Wu CL;Sequist LV;Smith MR;Ramaswamy S;Toner M;Maheswaran S;Haber DA
通讯作者：
Haber DA
从孕妇的外周血中分离出核红细胞（NRBC）的微流体方法。
影响因子：
3
作者：
Huang, R.;Barber, T. A.;Schmidt, M. A.;Tompkins, R. G.;Toner, M.;Bianchi, D. W.;Kapur, R.;Flejter, W. L.
通讯作者：
Flejter, W. L.
DOI：
10.1186/bcr2131
发表时间：
2008
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Deng G;Herrler M;Burgess D;Manna E;Krag D;Burke JF
通讯作者：
Burke JF
影响因子：
17.1
作者：
Stott SL;Lee RJ;Nagrath S;Yu M;Miyamoto DT;Ulkus L;Inserra EJ;Ulman M;Springer S;Nakamura Z;Moore AL;Tsukrov DI;Kempner ME;Dahl DM;Wu CL;Iafrate AJ;Smith MR;Tompkins RG;Sequist LV;Toner M;Haber DA;Maheswaran S
通讯作者：
Maheswaran S
DOI：
10.1073/pnas.0404036101
发表时间：
2004-07-20
影响因子：
11.1
作者：
Krivacic, RT;Ladanyi, A;Bruce, RH
通讯作者：
Bruce, RH